Sat, Jul 20, 2024
[Archive]
Volume 10, Issue 4 ( December 2018 2018)
Iranian Journal of Blood and Cancer 2018, 10(4): 114-116 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Gholipour H, Abroun S, Noruzinia M, Ghaffari S, Maali A, Azad M. Methylation Status of SMG1 Gene Promoter in Multiple Myeloma
. Iranian Journal of Blood and Cancer 2018; 10 (4) :114-116
URL: http://ijbc.ir/article-1-826-en.html
URL: http://ijbc.ir/article-1-826-en.html
Hamid Gholipour1 
, Saeid Abroun1 , Mehrdad Noruzinia1 , Sasan Ghaffari2 , Amirhosein Maali3 , Mehdi Azad * 3
, Saeid Abroun1 , Mehrdad Noruzinia1 , Sasan Ghaffari2 , Amirhosein Maali3 , Mehdi Azad * 3
1- Hematology Department, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2- Hematology Department, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran.
3- Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
2- Hematology Department, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran.
3- Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
Abstract: (3972 Views)
Background: Epigenetic modifications, such as methylation can occur in multiple myeloma. SMG1is an important gene involved in cell growth which defect in methylation of its promoter leads to reduction of cell apoptosis and uncontrolled proliferation. In this study, we identified the methylation status of the SMG1 gene promoter in patients with multiple myeloma.
Methods: Methylation status of SMG1 promoter in 9 patients with multiple myeloma and 4 healthy subjects as control was determined by Methylation-specific PCR (MSP) method.
Results: SMG1 promoter in all myeloma patients was hemi-methylated. Meanwhile, in healthy subjects, two cases were hemi-methylated and the other two were normal.
Conclusion: The results of this study indicated that the prevalence of SMG1 promoter methylation in patients with multiple myeloma was higher than general population which could be important in understanding the pathogenesis of the disease.
Methods: Methylation status of SMG1 promoter in 9 patients with multiple myeloma and 4 healthy subjects as control was determined by Methylation-specific PCR (MSP) method.
Results: SMG1 promoter in all myeloma patients was hemi-methylated. Meanwhile, in healthy subjects, two cases were hemi-methylated and the other two were normal.
Conclusion: The results of this study indicated that the prevalence of SMG1 promoter methylation in patients with multiple myeloma was higher than general population which could be important in understanding the pathogenesis of the disease.
: Original Article |
Subject:
Adults Hematology & Oncology
Received: 2018/09/7 | Accepted: 2018/11/10 | Published: 2019/01/5
Received: 2018/09/7 | Accepted: 2018/11/10 | Published: 2019/01/5
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
